An Overview of Insider Trading in the Clinical Trial Setting

Allan Horwich, Partner, ArentFox Schiff, and Crista Brawley, Associate Vice President for Research, Northwestern University, discuss insider trading in the clinical trial setting. They cover the basics of the law of insider trading, the regulatory process for the approval of a new drug by the FDA, confidentiality agreements, risks related to confidential information and disseminating information on public forums, and SEC enforcement. Allan and Crista recently authored an article for AHLA’s Journal of Health and Life Sciences Law about this issue.